Notable examples of synthetic compounds include the dipeptidyl peptidase IV inhibitor carmegliptin (2, DPP IV) with potential for the treatment of type-II diabetes [3–4]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.